225 related articles for article (PubMed ID: 38347650)
1. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
[TBL] [Abstract][Full Text] [Related]
2. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
[TBL] [Abstract][Full Text] [Related]
3. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese MC; Mysler E; Tomita T; Papp KA; Salvarani C; Schwartzman S; Gallo G; Patel H; Lisse JR; Kronbergs A; Leage SL; Adams DH; Xu W; Marzo-Ortega H; Lebwohl MG
Rheumatology (Oxford); 2020 Dec; 59(12):3834-3844. PubMed ID: 32449924
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
[TBL] [Abstract][Full Text] [Related]
6. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.
Combe B; Rahman P; Kameda H; Cañete JD; Gallo G; Agada N; Xu W; Genovese MC
Arthritis Res Ther; 2020 Jan; 22(1):14. PubMed ID: 31964419
[TBL] [Abstract][Full Text] [Related]
7. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
Feist E; Baraliakos X; Behrens F; Thaçi D; Plenske A; Klaus P; Meng T
Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
[TBL] [Abstract][Full Text] [Related]
8. Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies.
Aureal M; Seauve M; Laplane S; Lega JC; Cabrera N; Coury F
RMD Open; 2023 Sep; 9(3):. PubMed ID: 37714666
[TBL] [Abstract][Full Text] [Related]
9. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA.
Regierer AC; Weiß A; Proft F; Baraliakos X; Behrens F; Poddubnyy D; Schett G; Lorenz HM; Worsch M; Strangfeld A
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36898762
[TBL] [Abstract][Full Text] [Related]
10. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.
Rubbert-Roth A; Kakehasi AM; Takeuchi T; Schmalzing M; Palac H; Coombs D; Liu J; Anyanwu SI; Lippe R; Curtis JR
Rheumatol Ther; 2024 Feb; 11(1):97-112. PubMed ID: 37982966
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns and Healthcare Resource Utilization Among Newly Diagnosed Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, and Hidradenitis Suppurativa Patients with Past Diagnosis of an Inflammatory Condition: A Retrospective Cohort Analysis of Claims Data in the United States.
Hopson S; Gibbs LR; Syed S; Low R; McClung L; Beaty S
Adv Ther; 2023 Oct; 40(10):4358-4376. PubMed ID: 37486558
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.
Braun J; Kiltz U; Deodhar A; Tomita T; Dougados M; Bolce R; Sandoval D; Lin CY; Walsh J
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35853675
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry.
Ciurea A; Götschi A; Kissling S; Bernatschek A; Bürki K; Exer P; Nissen MJ; Möller B; Scherer A; Micheroli R
RMD Open; 2023 Jun; 9(2):. PubMed ID: 37277211
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2).
Orbai AM; Gratacós J; Turkiewicz A; Hall S; Dokoupilova E; Combe B; Nash P; Gallo G; Bertram CC; Gellett AM; Sprabery AT; Birt J; Macpherson L; Geneus VJ; Constantin A
Rheumatol Ther; 2021 Mar; 8(1):199-217. PubMed ID: 33278016
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab.
Egeberg A; Iversen L; Kimball AB; Kelly S; Grace E; Patel H; Xu W; Gallo G; Riedl E; Feldman SR
J Dermatolog Treat; 2022 Aug; 33(5):2503-2509. PubMed ID: 34547967
[TBL] [Abstract][Full Text] [Related]
16. Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure.
Griffiths CEM; Gooderham M; Colombel JF; Terui T; Accioly AP; Gallo G; Zhu D; Blauvelt A
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1431-1446. PubMed ID: 35624407
[TBL] [Abstract][Full Text] [Related]
17. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
Kroon FP; van der Burg LR; Ramiro S; Landewé RB; Buchbinder R; Falzon L; van der Heijde D
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010952. PubMed ID: 26186173
[TBL] [Abstract][Full Text] [Related]
18. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
[TBL] [Abstract][Full Text] [Related]
20. Ixekizumab for treating ankylosing spondylitis.
Kiwalkar S; Beier S; Deodhar A
Immunotherapy; 2019 Oct; 11(15):1273-1282. PubMed ID: 31530049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
